Coronavirus Breaking News

Philippine health authorities announced (NO.2026-0347) that they have dismantled an illegal manufacturing and distribution ring producing counterfeit anti-rabies vaccines during a coordinated raid in Taguig City.

The Philippine Food and Drug Administration (FDA), along with other agencies, executed a court-issued search warrant following weeks of surveillance and intelligence gathering. The raid uncovered an unlicensed facility involved in the falsification and repackaging of anti-rabies vaccines.

Items seized during the operation included counterfeit sticker labels, hologram adhesive tapes, vaccine cartons, unlabeled vials, and diluents intended to misrepresent the products as genuine.

FDA officials described the operation as a significant victory against the distribution of counterfeit medicines. Local officials believe the syndicate smuggled fake vaccines and concealed them among legitimate supplies to avoid detection.

Counterfeit or substandard rabies vaccines can fail to provide protection, leaving recipients vulnerable to rabies — a disease that is nearly 100% fatal once symptoms develop.

In the United States, rabies vaccines are strictly regulated by the U.S. FDA. The two primary human rabies vaccines currently approved are Imovax Rabies (human diploid cell vaccine) and RabAvert (purified chick embryo cell vaccine).

According to the U.S. Centers for Disease Control and Prevention (CDC), approximately 100,000 Americans receive rabies post-exposure prophylaxis (PEP) each year following potential exposure to the virus. PEP typically consists of wound care, human rabies immune globulin, and a four-dose vaccine series administered for previously unvaccinated individuals.

The CDC says an additional 1.4 million Americans seek medical evaluation annually for possible rabies exposures.

In the U.S., most rabies bites originate from bats.

Arizona health officials recently announced the confirmation of the county's first human case of plague since 2015.

This case, located in the northeast corner of Arizona, represents the fourth reported human plague case in Apache County since 2006. Most of the county is occupied by the Navajo Nation and the Fort Apache Indian Reservation.

Currently, the only known human plague infection reported in the United States for 2026.

The individual has fully recovered after receiving prompt medical treatment, according to the Apache County Public Health Services District statement.

Plague is a serious bacterial infection caused by Yersinia pestis. Humans most commonly contract it through the bite of infected fleas that live on wild rodents, such as prairie dogs and ground squirrels, which are prevalent in the southwestern United States.

There is currently no plague vaccine licensed or available for use by the general public in the United States. An earlier inactivated whole-cell plague vaccine was previously licensed but was discontinued decades ago due to side effects and limited effectiveness, particularly against pneumonic forms of the disease.

Several experimental plague vaccines are in development, including recombinant subunit vaccines (such as rF1V formulations in Phase 2 trials) and newer mRNA candidates. These vaccine candidates are primarily being studied for biodefense purposes or for high-risk groups such as laboratory workers, but none are being studied for widespread civilian use.

As of April 10, 2026, the U.S. The Centers for Disease Control and Prevention does not recommend routine vaccination against plague, even for residents in endemic areas like parts of Arizona, New Mexico, and Colorado.

In response to the Meningitis B (MenB) outbreak in Kent, the UK Health Security Agency (UKHSA) is expanding its efforts to provide preventive antibiotic treatment and vaccinations.

As of March 19, 2026, vaccination is now available for students (years 12 and 13) in schools and colleges with confirmed or probable cases of MenB.

Following an assessment by the local health protection team, antibiotics and vaccinations may also be offered to additional year groups. Students are encouraged to continue attending school as usual.

The vaccination extension also includes students at the University of Kent living on the Canterbury campus, close contacts of confirmed cases, and individuals who visited Club Chemistry in Canterbury in early March. The goal is to provide timely long-term protection for those at risk.

Professor Susan Hopkins from the UKHSA stated in a media release, "By extending the vaccination programme to those who have received antibiotics, we take an important step to protect those exposed."

Eligible individuals can request both the vaccination and antibiotics from their local GP.

Due to high demand for the private MenB vaccine, the NHS will release an additional 20,000 doses, enabling pharmacies to receive vaccines within 48 hours.

The UKHSA emphasizes that meningococcal disease, which includes meningitis and sepsis, is a serious but rare condition caused by meningococcal bacteria. Everyone is advised to remain vigilant for signs of severe illness and seek urgent medical attention if feeling unwell.

The smallest country in South America has reported a significant rise in chikungunya virus infections, with laboratory-confirmed cases exceeding 1,357 as of early March 2026.

According to a report from the Suriname Ministry of Health, local transmission of this mosquito-borne virus has resumed after nearly a decade without any reported autochthonous cases.

Local health authorities believe that the actual number of infections is likely much higher—potentially up to three times the confirmed figure, or around 4,000 cases—due to underreporting and typical health-seeking behaviors within the population. 

As of now, one death has been officially linked to chikungunya, while a second fatality is under investigation. In February 2026, the U.S. CDC issued a Level 2 Travel Health Notice, advising travelers to take enhanced precautions in light of the chikungunya outbreak in Suriname. 

While there is no specific antiviral treatment for chikungunya, approved vaccines are being offered in various countries as of March 24, 2026.

Argentine health authorities recently announced the country's first locally acquired case of mpox clade Ib. This development in Buenos Aires raises concerns about the potential for community transmission of this variant in South America.

The emergence of locally acquired clade Ib in Argentina underscores the virus's ability to establish transmission chains through sexual networks involving international travelers.

Buenos Aires, a major South American tourism hub, welcomed about 1.5 million foreign visitors last year.

The case, announced in report #9 on March 16, 2026, involves a man living in Buenos Aires who has no recent international travel history but reported sexual contact with multiple partners, including travelers, before the onset of symptoms. The patient is currently receiving outpatient treatment and is recovering. Contact tracing has begun, and there are recommendations for 21 days of follow-up monitoring.

Argentina's Ministry of Health has characterized clade Ib as being more severe and contagious than previous strains. They are urging health authorities to strengthen surveillance, ensure proper isolation until lesions have scabbed over, and provide healthcare workers with appropriate personal protective equipment.

Mpox first gained global attention in May 2022, primarily due to clade IIb of the virus. That outbreak resulted in over 100,000 confirmed cases worldwide across 122 countries, mostly transmitted sexually among men who have sex with men. Clade Ib differs from the milder clade IIb in terms of transmissibility.

In Argentina alone, approximately 1,129 confirmed cases and two deaths were reported between 2022 and early 2023. As of 2026, eight countries in the Americas, including Argentina, have reported a total of 172 mpox cases, with no deaths recorded to date.

As of March 20, 2026, effective mpox vaccines (JYNNEOS) are generally available in most countries.

The Department of State Health Services (DSHS) has launched a new sterilization program for dogs and cats to maximize the impact of sterilization across both urban and rural communities in Texas. 

DHSH confirmed on March 19, 2026, that the Texas Spay and Neuter Program has received $13 million from the legislature to fund this initiative for two years. Organizations selected for the program must employ or subcontract with a veterinarian who has significant spay-and-neuter experience.

Operating through 2026-2027, this pilot program is designed to protect human health by reducing the number of dogs and cats at risk of unplanned breeding, which can lead to the transmission of infectious diseases such as rabies. 

At least 33 confirmed animal rabies cases were reported by mid-March 2026.

From a local perspective, the most affected area in Texas was Travis County (Austin), with 68 cases in 2024, and patterns suggest a similar or higher number of cases in 2025.

From a disease prevention option for people, various clinics and pharmacies in Texas offer rabies vaccination services in 2026.

In addition to mitigating health risks for humans, spaying and neutering can also reduce the risk of cancer and other diseases in these animals. Research indicates that spayed and neutered cats and dogs tend to live longer on average.

For more information about the program, you can visit the Texas Spay and Neuter Program website.

Additionally, DSHS funds the Texas Animal Friendly Program, which assists communities in providing low-cost spay-and-neuter surgeries through the sale of custom Texas license plates that promote animal friendliness.

UK health officials today confirmed that they are investigating a concerning outbreak of invasive meningococcal disease in the Canterbury area of Kent, located in southeast England.

This outbreak involves invasive meningococcal disease, a serious bacterial infection that can lead to meningitis and septicaemia.

The UK Health Security Agency (UKHSA) reported that as of March 17, 2026, there have been 15 epidemiologically linked cases, including two fatalities.

Four of the cases have been laboratory-confirmed as group B meningococcal disease (MenB), which has been responsible for the majority of such infections in the UK in recent years. The remaining cases are still under investigation. Several affected individuals are students and are currently in serious condition in the hospital.

Close contacts of the confirmed cases are being traced and will be offered precautionary antibiotics to help limit the spread of the disease.

The UKHSA has linked many of the cases to social venues and networks in Canterbury, with reports suggesting that a significant number of infections can be traced back to visits to Club Chemistry nightclub between March 5 and 7, 2026.

The UKHSA emphasizes that there is currently no evidence of spread beyond the Kent area, and efforts are focused on containment.

Symptoms of meningococcal disease can develop quickly and may include fever, headache, stiff neck, vomiting, sensitivity to light, a non-blanching rash (which does not fade under pressure), and confusion. Authorities urge anyone experiencing these signs—especially young people and students—to seek urgent medical attention, as early treatment is critical.

Although meningococcal disease remains rare overall, this cluster highlights the ongoing risks among adolescents and young adults in close-contact settings like universities, says the UKHSA.

In response to this outbreak, which officials describe as "unprecedented" and "very unusual," a targeted vaccination program using the MenB vaccine will be implemented in the coming days for students living in halls at the University of Kent. Since 2015, the MenB vaccine has been available in the UK.

Trish Mannes, UKHSA Regional Deputy Director for the South East, commented in a press release, "Once again we remind anyone who visited Club Chemistry between 5 and 7 March to come forward for preventative antibiotic treatment as a precaution, as well as those offered antibiotics at the university."

As of March 17, 2026, the U.S. CDC has not issued a Travel Health Notice regarding this disease outbreak in the UK, nor has it issued vaccination recommendations.

In the U.S., the Bexsero® (MenB-4C) vaccine is available at clinics and pharmacies.